34.80
Schlusskurs vom Vortag:
$34.93
Offen:
$35.03
24-Stunden-Volumen:
1.04M
Relative Volume:
0.75
Marktkapitalisierung:
$2.74B
Einnahmen:
$399.58M
Nettoeinkommen (Verlust:
$-54.04M
KGV:
-46.40
EPS:
-0.75
Netto-Cashflow:
$40.13M
1W Leistung:
-3.33%
1M Leistung:
+12.91%
6M Leistung:
+15.04%
1J Leistung:
+7.84%
Veracyte Inc Stock (VCYT) Company Profile
Firmenname
Veracyte Inc
Sektor
Branche
Telefon
(650) 243-6300
Adresse
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie VCYT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VCYT
Veracyte Inc
|
34.80 | 2.75B | 399.58M | -54.04M | 40.13M | -0.75 |
![]()
TMO
Thermo Fisher Scientific Inc
|
524.80 | 201.90B | 43.21B | 6.58B | 6.17B | 17.28 |
![]()
DHR
Danaher Corp
|
202.46 | 146.42B | 24.01B | 3.41B | 4.86B | 4.7082 |
![]()
IDXX
Idexx Laboratories Inc
|
616.15 | 50.30B | 4.04B | 985.66M | 774.34M | 12.01 |
![]()
A
Agilent Technologies Inc
|
136.62 | 39.72B | 6.79B | 1.22B | 1.09B | 4.2644 |
![]()
IQV
Iqvia Holdings Inc
|
198.17 | 34.51B | 15.70B | 1.24B | 2.01B | 6.9036 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-20 | Eingeleitet | Craig Hallum | Buy |
2024-12-05 | Herabstufung | Goldman | Buy → Neutral |
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-10-16 | Eingeleitet | UBS | Buy |
2024-10-10 | Eingeleitet | Guggenheim | Buy |
2024-02-23 | Bestätigt | Needham | Buy |
2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
2022-01-07 | Eingeleitet | Stephens | Overweight |
2021-11-18 | Fortgesetzt | Goldman | Buy |
2021-06-15 | Eingeleitet | Raymond James | Outperform |
2021-02-18 | Fortgesetzt | Needham | Buy |
2021-01-28 | Eingeleitet | Truist | Buy |
2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2020-09-09 | Eingeleitet | Morgan Stanley | Underweight |
2019-07-31 | Eingeleitet | Lake Street | Buy |
2019-07-02 | Eingeleitet | Needham | Buy |
2018-11-29 | Herabstufung | Janney | Buy → Neutral |
2018-10-31 | Hochstufung | Janney | Neutral → Buy |
2017-11-07 | Herabstufung | Janney | Buy → Neutral |
2017-11-07 | Herabstufung | Piper Jaffray | Overweight → Neutral |
2017-08-31 | Fortgesetzt | BTIG Research | Buy |
2016-11-14 | Fortgesetzt | Leerink Partners | Outperform |
2015-12-18 | Eingeleitet | Cantor Fitzgerald | Buy |
2015-06-11 | Bestätigt | Leerink Partners | Outperform |
2013-11-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Veracyte Inc Aktie (VCYT) Neueste Nachrichten
How high can Veracyte Inc. stock goInsider Buying & Stock Portfolio Risk Control - newser.com
Veracyte Inc. stock daily chart insights2025 Earnings Impact & Real-Time Volume Analysis Alerts - newser.com
Veracyte Inc Stock Analysis and ForecastPrice Volatility Patterns & Rapid Capital Growth - earlytimes.in
What MACD signals say about Veracyte Inc.Trade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com
Real time social sentiment graph for Veracyte Inc.Layoff News & Daily Volume Surge Trade Alerts - newser.com
Has Veracyte Inc. formed a bullish divergenceJuly 2025 Summary & Real-Time Volume Triggers - newser.com
Why Veracyte Inc. (12V) stock stays on buy listsJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
Veracyte's (VCYT) Sell (D+) Rating Reaffirmed at Weiss Ratings - MarketBeat
Does Veracyte Inc. qualify in momentum factor screeningJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - newser.com
How supply chain issues affect Veracyte Inc. stockJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
What analyst consensus implies for Veracyte Inc. (12V) stockEarnings Recap Report & Fast Entry Momentum Alerts - newser.com
Veracyte (NASDAQ:VCYT) Upgraded to "Strong-Buy" at Zacks Research - MarketBeat
Veracyte, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
What analysts say about Veracyte Inc 12V stockStock Price Targets & Superior Capital Trading Plans - earlytimes.in
Insider Sell: Phillip Febbo Sells Shares of Veracyte Inc (VCYT) - GuruFocus
Veracyte (NASDAQ:VCYT) Insider Sells 8,349 Shares - MarketBeat
Is Veracyte Inc a good long term investmentStock Price Forecasts & Options Trading Analysis Tools - earlytimes.in
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar - Yahoo Finance
Will Veracyte (VCYT) Leverage PAM50 Data to Strengthen Its Position in Precision Oncology? - Sahm
Veracyte (VCYT): Reassessing Valuation After New BALANCE Trial Data Highlights Decipher’s Clinical Impact - Yahoo Finance
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Why Veracyte Inc. (12V) stock could break out in 2025Weekly Trade Review & Reliable Trade Execution Plans - newser.com
Using data tools to time your Veracyte Inc. exitWeekly Trend Summary & Safe Entry Trade Signal Reports - newser.com
How Veracyte Inc. (12V) stock compares with top peersEarnings Recap Report & Low Risk Entry Point Tips - newser.com
Can machine learning forecast Veracyte Inc. recoveryQuarterly Market Summary & Precise Trade Entry Recommendations - newser.com
Veracyte to replace Triumph in S&P SmallCap 600 index - MSN
Insider Sell Alert: John Leite Sells Shares of Veracyte Inc (VCY - GuruFocus
Veracyte started at buy by UBS, MRD platform cited - MSN
Veracyte Inc. stock outlook for YEAR2025 Bull vs Bear & Momentum Based Trading Signals - newser.com
Applying sector rotation models to Veracyte Inc.Portfolio Risk Summary & Real-Time Volume Trigger Notifications - newser.com
AMI Asset Management Corp Sells 8,580 Shares of Veracyte, Inc. $VCYT - MarketBeat
What analysts say about Veracyte Inc stockSector-Based Investing & Minimal Capital Investment - earlytimes.in
Veracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Finanzdaten der Veracyte Inc-Aktie (VCYT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):